The 2nd generation of a T-cell vaccine against HIV based on conserved region mosaics

The 2nd generation of a T-cell vaccine against HIV based on conserved region mosaics

Bibliographic Details
Main Authors:	Ondondo, B, Clutton, G, McMichael, A, Korber, B, Hanke, T
Format:	Journal article
Published:	2014

Similar Items

HIV-1 conserved mosaics delivered by regimens with integration-deficient, DC-targeting lentiviral vector induce robust T cells
by: Hanke, T, et al.
Published: (2016)

Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA
by: Nathifa Moyo, et al.
Published: (2019-03-01)

Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice.
by: Ondondo, B, et al.
Published: (2014)

Efficient induction of T cells against conserved HIV-1 regions by mosaic vaccines delivered as self-amplifying mRNA
by: Moyo, N, et al.
Published: (2018)

Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines
by: Edmund G. Wee, et al.
Published: (2021-06-01)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.
by: Borthwick, N, et al.
Published: (2014)

pTHr.HIVA and MVA.HIVA vaccines (gag p24/p17) augment CD4+T cell responses in chronically infected HIV-1 patients on HAART
by: Ondondo, B, et al.
Published: (2005)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1
by: Borthwick, N, et al.
Published: (2014)

Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping
by: Borthwick, N, et al.
Published: (2013)

Design and tests of an HIV vaccine.
by: McMichael, A, et al.
Published: (2002)

The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial
by: Ondondo, B, et al.
Published: (2013)

Is an HIV vaccine possible?
by: Mcmichael, A, et al.
Published: (1999)

Control of HIV-1 by CD8+T cells specific for epitopes of conserved mosaic vaccine immunogens
by: Murakoshi, H, et al.
Published: (2018)

HIV T cell vaccines, the importance of clades.
by: McMichael, A, et al.
Published: (2002)

Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines.
by: Hanke, T
Published: (2014)

HIV vaccines 1983-2003.
by: Mcmichael, A, et al.
Published: (2003)

Effective suppression of HIV-1 replication by cytotoxic T lymphocytes specific for pol epitopes in conserved mosaic vaccine immunogens
by: Zou, C, et al.
Published: (2019)

Targeting HIV-1 where it hurts
by: Borthwick, N, et al.
Published: (2013)

HIV-host interactions: implications for vaccine design
by: Haynes, B, et al.
Published: (2016)

Design and pre-clinical evaluation of a universal HIV-1 vaccine.
by: Létourneau, S, et al.
Published: (2007)

Development of a Universal T Cell Vaccine
by: Rosario, M, et al.
Published: (2008)

Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.
by: Rosario, M, et al.
Published: (2010)

The Influence of Delivery Vectors on HIV Vaccine Efficacy
by: Beatrice Omusiro Ondondo
Published: (2014-08-01)

Targeting HIV-1 Where It Hurts
by: Ahmed, T, et al.
Published: (2013)

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.
by: Hanke, T, et al.
Published: (2000)

DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice.
by: Hanke, T, et al.
Published: (1998)

DNA vaccines against human immunodeficiency virus type 1.
by: Estcourt, M, et al.
Published: (2004)

Design and pre-clinical evaluation of a universal HIV-1 vaccine.
by: Sven Létourneau, et al.
Published: (2007-10-01)

Aiming for protective T-cell responses: A focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials
by: Hanke, T
Published: (2019)

The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
by: McMichael, A, et al.
Published: (2002)

Parallel induction of CH505 B cell ontogeny-guided neutralizing antibodies and tHIVconsvX conserved mosaic-specific T cells against HIV-1
by: Wee, E, et al.
Published: (2019)

Correction: Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine.
by: Sven Létourneau, et al.
Published: (2011-01-01)

MVA as a vector for vaccines against HIV-1.
by: Im, E, et al.
Published: (2004)

Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy.
by: Yang, H, et al.
Published: (2007)

Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines.
by: Mwau, M, et al.
Published: (2002)

A greater breadth of HIV-1-specific T cell responses detected using mosaic peptides compare to consensus peptides
by: Yang, H, et al.
Published: (2009)

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.
by: Dorrell, L, et al.
Published: (2006)

Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions
by: Jakub Kopycinski, et al.
Published: (2023-10-01)

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS.
by: Hanke, T, et al.
Published: (1999)

Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
by: Haynes, BF, et al.
Published: (2022)